Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The move follows the company's decision to combine the Chief Operating Officer roles for Drug Substances and Drug Products into a single position, aligning with its strategy to offer integrated end-to-end solutions across the pharmaceutical value chain, from drug substances to drug products.
Eduardo Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks. Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management, and has lived and worked across Europe and Latin America.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, commented: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
This appointment underscores Siegfried's commitment to strengthening its operational capabilities as a CDMO with 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia and China. In 2025, the company achieved sales of CHF 1,327.8 million and employed more than 3,800 people. For more information, visit www.siegfried.ch or view the original release on www.newmediawire.com.
